NucleoTech
Effective Drug Delivery to the Brain
StartupNucleoTech is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2023. Effective Drug Delivery to the Brain. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
The company follows a B2B business model. Product stage: R&D.
- StagePre-Funding
- ProductR&D
- ModelB2B
- Employees1-10
- HQRehovot
- Last RoundUndisclosed
What does NucleoTech do?
To date, many brain conditions are poorly medicated due to limitations in drug-delivery prevent treating patients efficiently. The prominent reason is the Blood Brain Barrier (BBB), which prevents most therapeutic molecules from reaching the brain – and severely limits the arsenal of brain therapeutics. NucleoTech is developing carriers that deliver a variety of drug-classes across the BBB, including biologics and RNA drugs. The company utilizes the BBBs own transfer mechanisms to allow therapeutic molecules through, by using nanobodies (also called Single Domain Antibodies) as carrier molecules that shuttle therapeutics into the brain by the process of Receptor-Mediated Transcytosis.
What sector is NucleoTech in?
NucleoTech operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is NucleoTech located?
NucleoTech is based in Rehovot, Israel. The company also has offices abroad.